Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00083239 · ClinicalTrials.gov registry record · Phase 2

Study of Talabostat in Advanced Melanoma

A Phase 2 study, sponsored by Point Therapeutics.

Completed
Registry status
Phase 2
Development phase

NCT00083239: Completed Phase 2 study, sponsored by Point Therapeutics.

NCT00083239 is a Phase 2 study that has completed, run by Point Therapeutics. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00083239, a Phase 2 study, has completed, sponsored by Point Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

The purpose of this study is to assess the antitumor activity and safety of talabostat in patients with metastatic melanoma.

Interventions

  • DRUG talabostat (PT-100) tablets

Trial Details

FieldValue
Phase Phase 2
Point Therapeutics

7 total trials

What the finished NCT00083239 record still lists

NCT00083239 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which talabostat (PT-100) tablets is the first listed.

NCT00083239 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00083239 about?

NCT00083239 is a clinical study titled "Study of Talabostat in Advanced Melanoma". The purpose of this study is to assess the antitumor activity and safety of talabostat in patients with metastatic melanoma.

What is the current status of trial NCT00083239?

This trial is currently completed. It is a Phase 2 study.

What interventions are being tested in trial NCT00083239?

The interventions under investigation include: talabostat (PT-100) tablets (DRUG).

Who is sponsoring clinical trial NCT00083239?

This trial is sponsored by Point Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Learn More About Clinical Trials

Source: ClinicalTrials.gov NCT00083239, the US trial registry maintained by the National Library of Medicine. NCT00083239 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.